Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – Among patients undergoing liver transplantation for hepatocellular carcinoma, the risk of recurrence is lower when immunosuppression is based on sirolimus rather than calcineurin…
NEW YORK (Reuters Health) – A French team reports some advantages with robot-assisted compared to conventional laparoscopic radical prostatectomy performed via an extraperitoneal approach. “This study did not…
Lee Krug, MD, discusses the current state of mesothelioma treatments as well as new therapies in development. He mentions the possibilities of clinical trials for angiogenesis inhibitors and anti-VEGF antibodies for mesothelioma…
N. Anthony Coles, MD, President and CEO of Onyx Pharmaceuticals, discusses how developments in genomics and personalized medicine can pave the way for the future of drug development.…
John Driscoll, President of Castlight Health, explains how to improve healthcare in the United States through transparency. This interview was conducted at the Forbes Healthcare Summit 2012. Read more…
Sandra Fenwick, CEO of Boston Children’s Hospital, discusses new ways that hospitals and doctors are partnering to focus on managing care for patients. This interview was conducted at…
More than 2700 people lost their lives during the terrorist attacks on the World Trade Center in New York City. The attack also exposed hundreds of thousands of…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to FOLFOX chemotherapy does not improve outcomes in patients with stage II-III colon cancer, according to a…
Oriane Chausiaux, PhD, and Shamus Husheer, PhD, explain the hardships faced by 1 in 7 American couples who have difficulties with fertility. These issues range from a lack of…
ZURICH (Reuters) – Swiss pharma group Roche’s drug Perjeta (pertuzumab) significantly extended the lives of women with HER2-positive breast cancer compared to a placebo, according to new data…
